BACKGROUND: Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals. METHODS: We assayed serum concentrations of soluble mesothelin-related proteins (SMR) using a double determinant (sandwich) ELISA in a blinded study of serum samples from 44 patients with histologically proven mesothelioma; 68 matched healthy controls, 40 of whom had been exposed to asbestos; and 160 patients with other inflammatory or malignant lung and pleural diseases. FINDINGS: 37 (84%) of 44 patients with mesothelioma had raised concentrations of SMR at a serum dilution of 1/80, compared with three (2%) of 160 patients with other cancers or other inflammatory lung or pleural diseases, and with none of 28 controls who had not been exposed to asbestos. SMR concentrations correlated with tumour size and increased during tumour progression. Seven of the 40 asbestos-exposed individuals had increased serum concentrations of SMR; three of those seven developed mesothelioma and one developed lung carcinoma within 1-5 years. None of the 33 asbestos-exposed participants whose serum samples had normal concentrations of SMR and who were followed up over 8 years developed mesothelioma. INTERPRETATION: Determination of SMR in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression. It might also prove helpful for screening asbestos-exposed individuals for early evidence of mesothelioma.
BACKGROUND:Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals. METHODS: We assayed serum concentrations of soluble mesothelin-related proteins (SMR) using a double determinant (sandwich) ELISA in a blinded study of serum samples from 44 patients with histologically proven mesothelioma; 68 matched healthy controls, 40 of whom had been exposed to asbestos; and 160 patients with other inflammatory or malignant lung and pleural diseases. FINDINGS: 37 (84%) of 44 patients with mesothelioma had raised concentrations of SMR at a serum dilution of 1/80, compared with three (2%) of 160 patients with other cancers or other inflammatory lung or pleural diseases, and with none of 28 controls who had not been exposed to asbestos. SMR concentrations correlated with tumour size and increased during tumour progression. Seven of the 40 asbestos-exposed individuals had increased serum concentrations of SMR; three of those seven developed mesothelioma and one developed lung carcinoma within 1-5 years. None of the 33 asbestos-exposed participants whose serum samples had normal concentrations of SMR and who were followed up over 8 years developed mesothelioma. INTERPRETATION: Determination of SMR in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression. It might also prove helpful for screening asbestos-exposed individuals for early evidence of mesothelioma.
Authors: Elad Sharon; Jingli Zhang; Kevin Hollevoet; Seth M Steinberg; Ira Pastan; Masanori Onda; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan Journal: Clin Chem Lab Med Date: 2012-04 Impact factor: 3.694
Authors: Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman Journal: J Histochem Cytochem Date: 2012-06-21 Impact factor: 2.479
Authors: Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru Journal: Clin Cancer Res Date: 2010-10-29 Impact factor: 12.531
Authors: Nathalie Scholler; Kimberly A Lowe; Lindsay A Bergan; Archana V Kampani; Vivian Ng; Robin M Forrest; Jason D Thorpe; Jenny A Gross; Barbara M Garvik; Ronny Drapkin; Garnet L Anderson; Nicole Urban Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Michael K Felten; Khaled Khatab; Lars Knoll; Thomas Schettgen; Hendrik Müller-Berndorff; Thomas Kraus Journal: Int Arch Occup Environ Health Date: 2013-02-20 Impact factor: 3.015